Close Menu

NEW YORK (GenomeWeb) – Following a bankruptcy proceeding that began a few years ago, ZyGem has found a home as part of a new UK company that is taking a chance on the firm and its affiliate Microlab, intent on focusing on ZyGem's unique sample-prep capabilities with a longer-term goal of expanding on work toward a platform for the forensics market.

ZyGem and Microlab are now part of MicroGem International, a firm publicly traded in the UK that acquired the assets of ZyGem and MicroLab last year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.

GenomeWeb reports that Veritas Genetics is suspending its US operations.

A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.

In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.

Dec
17
Sponsored by
Thermo Fisher Scientific

This webinar will review how liquid biopsy can be considered as an alternative and non-invasive method to tissue biopsy for cancer molecular characterization.

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.